Silco Pharmaceuticals（SILCOPHL）株式概要シルコ・ファーマシューティカルズ・リミテッドは、バングラデシュ内外で完成医薬品の製造・販売を行っている。 詳細SILCOPHL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金2/6リスク分析過去5年間で収益は年間18.8%減少しました。 意味のある時価総額がありません ( BDT2B )意味のある収益がありません ( BDT409M )BD市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るSILCOPHL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value৳Current Price৳21.30252.1% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0920m2016201920222025202620282031Revenue ৳259.7mEarnings ৳21.7mAdvancedSet Fair ValueView all narrativesSilco Pharmaceuticals Limited 競合他社Advent PharmaSymbol: DSE:ADVENTMarket cap: ৳1.4bTechno DrugsSymbol: DSE:TECHNODRUGMarket cap: ৳5.6bOrion InfusionSymbol: DSE:ORIONINFUMarket cap: ৳6.4bNavana PharmaceuticalsSymbol: DSE:NAVANAPHARMarket cap: ৳7.6b価格と性能株価の高値、安値、推移の概要Silco Pharmaceuticals過去の株価現在の株価৳21.3052週高値৳22.6052週安値৳11.10ベータ0.251ヶ月の変化28.31%3ヶ月変化52.14%1年変化39.22%3年間の変化-12.70%5年間の変化-17.44%IPOからの変化-6.65%最新ニュースValuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.お知らせ • Nov 18Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026, at 11:30 Central Asia Standard Time. Location: hybrid system:, at registered office premises., Bangladeshお知らせ • Nov 11Silco Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Nov 17, 2025Silco Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Nov 17, 2025お知らせ • Apr 21Silco Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silco Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025お知らせ • Jan 27Silco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025お知らせ • Nov 18Silco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 21, 2024Silco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 21, 2024New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Revenue is less than US$5m (৳422m revenue, or US$3.5m). Market cap is less than US$100m (৳1.63b market cap, or US$13.6m).Declared Dividend • Nov 06Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 9th December 2024 Payment date: 16th February 2025 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (66% earnings payout ratio) but not adequately covered by cash flows (92% cash payout ratio). The dividend has increased by an average of 13% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 27% to shift the payout ratio to a potentially unsustainable range, which is more than the 23% EPS decline seen over the last 5 years.お知らせ • Nov 04Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladeshお知らせ • Oct 25Silco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 31, 2024Silco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳21.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 27% over the past three years.Valuation Update With 7 Day Price Move • May 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ৳21.30, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 7.5% over the past three years.Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.16 (vs ৳0.21 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.16 (down from ৳0.21 in 3Q 2023). Revenue: ৳110.0m (down 12% from 3Q 2023). Net income: ৳17.1m (down 21% from 3Q 2023). Profit margin: 16% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Apr 26Silco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Silco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 08Second quarter 2024 earnings released: EPS: ৳0.12 (vs ৳0.15 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.12 (down from ৳0.15 in 2Q 2023). Revenue: ৳104.9m (flat on 2Q 2023). Net income: ৳12.8m (down 19% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.80, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.8% over the past three years.お知らせ • Jan 24Silco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 30, 2024Silco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 30, 2024New Risk • Jan 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (157% cash payout ratio). Large one-off items impacting financial results. Revenue is less than US$5m (৳437m revenue, or US$4.0m). Market cap is less than US$100m (৳2.43b market cap, or US$22.2m).Upcoming Dividend • Dec 12Upcoming dividend of ৳0.30 per share at 1.3% yieldEligible shareholders must have bought the stock before 19 December 2023. Payment date: 12 February 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.43b market cap, or US$22.1m).お知らせ • Nov 29Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023Silco Pharmaceuticals Limited recommended 3% cash dividend for all shareholders excluding Directors for the year ended June 30, 2023.お知らせ • Nov 28Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024, at 11:30 Bangladesh Standard Time. Agenda: To approve the Dividend Declaration.お知らせ • Nov 27Silco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 29, 2023Silco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 29, 2023お知らせ • Nov 20Silco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Nov 26, 2023Silco Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Nov 26, 2023New Risk • Jun 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳418m (US$3.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.47b market cap, or US$22.7m).Buying Opportunity • May 29Now 22% undervaluedOver the last 90 days, the stock is up 4.7%. The fair value is estimated to be ৳31.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has grown by 4.4%.お知らせ • Jan 12Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited approved 5% cash dividend for the year ended June 30, 2022.Upcoming Dividend • Nov 29Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 06 December 2022. Payment date: 09 February 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.3%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 08Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited announced that the Board of Directors has recommended 5% cash dividend for all shareholders excluding Directors only for the year ended June 30, 2022.Buying Opportunity • Jul 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.2%. The fair value is estimated to be ৳29.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last year. Earnings per share has declined by 50%.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.40, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 29% over the past year.Reported Earnings • May 29Third quarter 2021 earnings released: EPS: ৳0.32 (vs ৳0.25 in 3Q 2020)Third quarter 2021 results: EPS: ৳0.32 (up from ৳0.25 in 3Q 2020). Revenue: ৳188.7m (down 5.1% from 3Q 2020). Net income: ৳33.3m (up 28% from 3Q 2020). Profit margin: 18% (up from 13% in 3Q 2020). The increase in margin was driven by lower expenses.Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 5.7%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Buying Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.5%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Apr 04Now 20% undervaluedOver the last 90 days, the stock is up 4.4%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳27.10, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 17% over the past year.Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% per annum over the last 3 years. Earnings per share has declined by 25% per annum over the last 3 years.Upcoming Dividend • Dec 14Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 15 February 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Within top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳30.90, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 44% over the past year.Reported Earnings • Feb 24Second quarter 2021 earnings released: EPS ৳0.12 (vs ৳0.23 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳121.3m (down 29% from 2Q 2020). Net income: ৳12.4m (down 48% from 2Q 2020). Profit margin: 10% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue.お知らせ • Nov 03Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time. Agenda: To recommend cash dividend for the year ended on June 30, 2020.お知らせ • Oct 05Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil LtdSilco Pharmaceuticals Limited signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be USD 3,80,000.00. First export value (as per PI) will be USD 26,780.00 against 13 different medicines to Afghanistan and estimated profit will be 30% against the export.お知らせ • Jul 06Silco Pharmaceuticals Limited to Report Q3, 2020 Results on Jun 29, 2020Silco Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jun 29, 2020株主還元SILCOPHLBD PharmaceuticalsBD 市場7D0.5%1.7%0.2%1Y39.2%13.2%11.0%株主還元を見る業界別リターン: SILCOPHL過去 1 年間で13.2 % の収益を上げたBD Pharmaceuticals業界を上回りました。リターン対市場: SILCOPHL過去 1 年間で11 % の収益を上げたBD市場を上回りました。価格変動Is SILCOPHL's price volatile compared to industry and market?SILCOPHL volatilitySILCOPHL Average Weekly Movement7.2%Pharmaceuticals Industry Average Movement4.1%Market Average Movement4.9%10% most volatile stocks in BD Market7.5%10% least volatile stocks in BD Market2.8%安定した株価: SILCOPHLの株価は、 BD市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SILCOPHLの weekly volatility ( 7% ) は過去 1 年間安定していますが、依然としてBDの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995313Md. Haque Rukanwww.silcopharma.comシルコ・ファーマシューティカルズ・リミテッドは、バングラデシュ内外で完成医薬品の製造・販売を行っている。抗潰瘍剤、抗不安剤、カルシウム剤とその配合剤、中枢性筋弛緩剤、利尿剤、消化管運動促進剤、血液浄化剤、ビタミン・ミネラル剤、下剤、脂質低下剤、解熱去痰剤、非ステロイド性抗炎症剤、麻薬、マルチメディシン。また、アフガニスタン、ブータン、ミャンマー、コートジボワール、ケニア、モーリシャス、ソマリア、タンザニア、ウガンダに医薬品を輸出している。シルコ・ファーマシューティカルズ・リミテッドは1995年に設立され、バングラデシュのシレットに本社を置いている。もっと見るSilco Pharmaceuticals Limited 基礎のまとめSilco Pharmaceuticals の収益と売上を時価総額と比較するとどうか。SILCOPHL 基礎統計学時価総額৳2.21b収益（TTM）৳34.23m売上高(TTM)৳408.71m64.6xPER（株価収益率5.4xP/SレシオSILCOPHL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SILCOPHL 損益計算書（TTM）収益৳408.71m売上原価৳269.40m売上総利益৳139.31mその他の費用৳105.08m収益৳34.23m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.33グロス・マージン34.09%純利益率8.37%有利子負債／自己資本比率0%SILCOPHL の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.5%現在の配当利回り27%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 08:19終値2026/06/16 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Silco Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025
お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.
Valuation Update With 7 Day Price Move • Jun 05Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ৳19.20, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 21% over the past three years.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 24Silco Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 29, 2026Silco Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 26Silco Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silco Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 25Silco Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 30, 2025Silco Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 30, 2025
お知らせ • Nov 19Silco Pharmaceuticals Limited announces Annual dividend, payable on February 18, 2026Silco Pharmaceuticals Limited announced Annual dividend of BDT 0.1100 per share payable on February 18, 2026, ex-date on December 17, 2025 and record date on December 15, 2025.
お知らせ • Nov 18Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026Silco Pharmaceuticals Limited, Annual General Meeting, Jan 19, 2026, at 11:30 Central Asia Standard Time. Location: hybrid system:, at registered office premises., Bangladesh
お知らせ • Nov 11Silco Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Nov 17, 2025Silco Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Nov 17, 2025
お知らせ • Apr 21Silco Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silco Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
お知らせ • Jan 27Silco Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silco Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Nov 18Silco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 21, 2024Silco Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 21, 2024
New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (10% net profit margin). Revenue is less than US$5m (৳422m revenue, or US$3.5m). Market cap is less than US$100m (৳1.63b market cap, or US$13.6m).
Declared Dividend • Nov 06Dividend of ৳0.10 announcedShareholders will receive a dividend of ৳0.10. Ex-date: 9th December 2024 Payment date: 16th February 2025 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (66% earnings payout ratio) but not adequately covered by cash flows (92% cash payout ratio). The dividend has increased by an average of 13% per year over the past 4 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 27% to shift the payout ratio to a potentially unsustainable range, which is more than the 23% EPS decline seen over the last 5 years.
お知らせ • Nov 04Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025Silco Pharmaceuticals Limited, Annual General Meeting, Jan 16, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
お知らせ • Oct 25Silco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 31, 2024Silco Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Jul 05Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ৳21.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 27% over the past three years.
Valuation Update With 7 Day Price Move • May 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ৳21.30, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 7.5% over the past three years.
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.16 (vs ৳0.21 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.16 (down from ৳0.21 in 3Q 2023). Revenue: ৳110.0m (down 12% from 3Q 2023). Net income: ৳17.1m (down 21% from 3Q 2023). Profit margin: 16% (down from 18% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 26Silco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024Silco Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 08Second quarter 2024 earnings released: EPS: ৳0.12 (vs ৳0.15 in 2Q 2023)Second quarter 2024 results: EPS: ৳0.12 (down from ৳0.15 in 2Q 2023). Revenue: ৳104.9m (flat on 2Q 2023). Net income: ৳12.8m (down 19% from 2Q 2023). Profit margin: 12% (down from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ৳19.80, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 4.8% over the past three years.
お知らせ • Jan 24Silco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 30, 2024Silco Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 30, 2024
New Risk • Jan 09New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (157% cash payout ratio). Large one-off items impacting financial results. Revenue is less than US$5m (৳437m revenue, or US$4.0m). Market cap is less than US$100m (৳2.43b market cap, or US$22.2m).
Upcoming Dividend • Dec 12Upcoming dividend of ৳0.30 per share at 1.3% yieldEligible shareholders must have bought the stock before 19 December 2023. Payment date: 12 February 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
New Risk • Dec 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.43b market cap, or US$22.1m).
お知らせ • Nov 29Silco Pharmaceuticals Limited Recommends Cash Dividend for All Shareholders Excluding Directors for the Year Ended June 30, 2023Silco Pharmaceuticals Limited recommended 3% cash dividend for all shareholders excluding Directors for the year ended June 30, 2023.
お知らせ • Nov 28Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024Silco Pharmaceuticals Limited, Annual General Meeting, Jan 13, 2024, at 11:30 Bangladesh Standard Time. Agenda: To approve the Dividend Declaration.
お知らせ • Nov 27Silco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 29, 2023Silco Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 29, 2023
お知らせ • Nov 20Silco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Nov 26, 2023Silco Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Nov 26, 2023
New Risk • Jun 15New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ৳418m (US$3.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (৳418m revenue, or US$3.8m). Market cap is less than US$100m (৳2.47b market cap, or US$22.7m).
Buying Opportunity • May 29Now 22% undervaluedOver the last 90 days, the stock is up 4.7%. The fair value is estimated to be ৳31.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 19% over the last year. Earnings per share has grown by 4.4%.
お知らせ • Jan 12Silco Pharmaceuticals Limited Approves Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited approved 5% cash dividend for the year ended June 30, 2022.
Upcoming Dividend • Nov 29Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 06 December 2022. Payment date: 09 February 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.3%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.5%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 08Silco Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022Silco Pharmaceuticals Limited announced that the Board of Directors has recommended 5% cash dividend for all shareholders excluding Directors only for the year ended June 30, 2022.
Buying Opportunity • Jul 24Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.2%. The fair value is estimated to be ৳29.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 16% over the last year. Earnings per share has declined by 50%.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳30.40, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 29% over the past year.
Reported Earnings • May 29Third quarter 2021 earnings released: EPS: ৳0.32 (vs ৳0.25 in 3Q 2020)Third quarter 2021 results: EPS: ৳0.32 (up from ৳0.25 in 3Q 2020). Revenue: ৳188.7m (down 5.1% from 3Q 2020). Net income: ৳33.3m (up 28% from 3Q 2020). Profit margin: 18% (up from 13% in 3Q 2020). The increase in margin was driven by lower expenses.
Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 5.7%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Buying Opportunity • May 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.5%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Apr 04Now 20% undervaluedOver the last 90 days, the stock is up 4.4%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 18% over the last year. Earnings per share has declined by 53%.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳27.10, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 17% over the past year.
Buying Opportunity • Feb 15Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.9%. The fair value is estimated to be ৳32.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 12% per annum over the last 3 years. Earnings per share has declined by 25% per annum over the last 3 years.
Upcoming Dividend • Dec 14Upcoming dividend of ৳1.00 per shareEligible shareholders must have bought the stock before 21 December 2021. Payment date: 15 February 2022. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Within top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳30.90, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 44% over the past year.
Reported Earnings • Feb 24Second quarter 2021 earnings released: EPS ৳0.12 (vs ৳0.23 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳121.3m (down 29% from 2Q 2020). Net income: ৳12.4m (down 48% from 2Q 2020). Profit margin: 10% (down from 14% in 2Q 2020). The decrease in margin was driven by lower revenue.
お知らせ • Nov 03Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020Silco Pharmaceuticals Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time. Agenda: To recommend cash dividend for the year ended on June 30, 2020.
お知らせ • Oct 05Silco Pharmaceuticals Limited Signs First Export Agreement with Zaid Elyas Adil LtdSilco Pharmaceuticals Limited signed its first export agreement with ZAID ELYAS ADIL LTD, Afghanistan. The Company will export total of 13 different medicines to Afghanistan for next 5 years commencing from August 2020. Total export value (estimated) will be USD 3,80,000.00. First export value (as per PI) will be USD 26,780.00 against 13 different medicines to Afghanistan and estimated profit will be 30% against the export.
お知らせ • Jul 06Silco Pharmaceuticals Limited to Report Q3, 2020 Results on Jun 29, 2020Silco Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jun 29, 2020
